<DOC>
	<DOCNO>NCT00701415</DOCNO>
	<brief_summary>The purpose study determine whether 2 alternative dose regimen Fabrazyme ( Agalsidase beta ) ( 1.0 mg/kg every 4 week 0.5 mg/kg every 2 week ) effective treatment-naïve pediatric participant without severe symptom . Participants treat 5 year .</brief_summary>
	<brief_title>A Study Two Fabrazyme ( Agalsidase Beta ) Dosing Regimens Treatment-naïve , Male Pediatric Patients Without Severe Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Fabry Disease</mesh_term>
	<criteria>The participant and/or participant 's parent ( ) /legal guardian ( ) must provide write informed assent/consent prior protocolrelated procedure perform . The participant must confirm diagnosis Fabry disease document leukocyte αGalactosidase A ( αGAL ) activity &lt; 4 nmol/hr/mg leukocyte ( preferred assay ; result central laboratory ) . If leukocyte αGAL activity assay difficult obtain , participant might enrol base documented plasma αGAL &lt; 1.5 nmol/hr/mL , agreement Medical Monitor ( resulted central laboratory ) . The participant must evidence globotriaosylceramide ( GL3 ) accumulation document plasma GL3 ( &gt; 7.0 µg/mL ) urinary GL3 ( &gt; 0.3 mg GL3/mmol creatinine ) level ( result central laboratory ) . The participant must male ≥5 ≤18 year age . Participant albuminuria ( first morning void urinary albumin/creatinine ratio &gt; 30 mg/g least 2 3 consecutive sample , least 1 week apart ) . Participant Glomerular Filtration Rate ( GFR ) iohexol &lt; 90 L/min/1.73m^2 . In case properly document low protein intake , value low 80 mL/min/1.73 m^2 might acceptable , consultation Medical Monitor . Participant document evidence stroke transient ischemic attack ( TIA ) , brain magnetic resonance imaging ( MRI ) perform , bright lesion &gt; 2 mm T2 fluid attenuate inversion recovery ( FLAIR ) weight image within white matter basal ganglion . Participant severe recurrent acroparesthesia , judge physician frequent ( week ) pain episode least 3 month influence daily activity , irrespective medication . Participant enddiastolic leave ventricular posterior wall thickness ( LVPWTd ) and/or enddiastolic interventricular septum thickness ( IVSTd ) ≥2 standard deviation ( SD ) compare normal ( base body surface area [ BSA ] normal range Kampmann , et al 2000 ) read study site . Participant receive prior treatment specific Fabry Disease . Participant participate study employ investigational drug within 30 day start participation study . Participant medical condition extenuate circumstance , opinion Study Investigator , could interfere study compliance . Participant medical condition extenuate circumstance , example diabetes mellitus , opinion Study Investigator , could interfere interpretation study result . Participant treatment angiotensin convert enzyme inhibitors/angiotensin receptor blocker ( ACEIs/ARBs ) . Participant contraindication mention label Fabrazyme and/or iohexol ( Omnipaque ) . Participant parent ( ) /legal guardian ( ) unwilling comply requirement protocol .</criteria>
	<gender>Male</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>α-GAL , α-Galactosidase-A , r-hαGAL</keyword>
</DOC>